Hong Kong Sanatorium & Hospital
Hong Kong Sanatorium & Hospital
News Article | May 23, 2017
The update includes various enhancements and new features such as enhanced display management tools for quick swapping of n number of follow-up exams, dedicated reports for tracking each patient's findings for referrers, a new dictation software integration focused on transferring findings statistics to reports, new contouring tools, and much more. Some of the institutions currently utilizing MIM Encore clinically include Beth Israel Deaconess Medical Center, Hong Kong Sanatorium & Hospital, Mayo Clinic, Peter MacCallum Cancer Centre, Stanford Health Care, UAB Hospital, and the University of Virginia Health System. MIM Software will be demonstrating MIM Encore at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting June 10-13 in Denver, CO. MIM Software Inc. provides practical imaging solutions in the fields of radiation oncology, radiology, nuclear medicine, neuroimaging, and cardiac imaging. MIM offers solutions for PC and Mac® workstations as well as mobile iOS and cloud-based platforms. MIM is a privately held company that sells its products globally to imaging centers, hospitals, specialty clinics, research organizations, and pharmaceutical companies. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/mim-software-inc-announces-updates-to-mim-encore-300462320.html
News Article | December 21, 2016
SUNNYVALE, Calif., Dec. 21, 2016 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) has signed an agreement with Hong Kong Sanatorium & Hospital (HKSH) for the acquisition of three Radixact™ Systems that will provide clinicians and their patients with access to the newest advanced radiation therapy. Of the three Radixact Systems, two will replace existing TomoTherapy® Systems and one will be installed in a new bunker. The agreement also includes an upgrade of HKSH's existing CyberKnife® M6™ System to include the latest features for motion management and treatment efficiency, and was entered into backlog during Accuray's second fiscal quarter which ends December 31, 2016. The agreement with HKSH will make Radixact, the next-generation helical radiation therapy technology, available for the full range of cancer patients being treated at this private hospital system known for high quality patient care based on advanced knowledge, expertise and technology. The system will enable the HKSH clinical team to more efficiently and effectively deliver precise radiation treatments, and to confidently adapt therapy to changes in tumor size, shape and location -- as well as subtle changes in the location of organs and other healthy tissue. "HKSH has a well-earned reputation for high-quality patient care based on advanced knowledge, expertise and technology. We are honored to expand Accuray's role in helping their team meet the needs of their rapidly growing patient population. HKSH will be the first hospital in Asia to have both the Radixact and CyberKnife M6 Systems available for patient treatments. This commitment shows confidence in our new Radixact System and in the Accuray team's ability to help the Hospital provide 'Quality in Service; Excellence in Care,'" said Josh Levine, President and Chief Executive Officer of Accuray. "We are excited to build on the previous experience we have had with the TomoTherapy platform by moving to the next generation helical platform from Accuray. The TomoTherapy platform has enabled us to treat a wide range of cancer patients. The CyberKnife M6 and Radixact Systems, together, are complementary technologies that will enable us to offer each cancer patient the advanced radiation therapy best suited to precisely treating their disease while minimizing side effects," said Mr. Wyman Li, Manager (Administration) of HKSH. "Hong Kong Sanatorium & Hospital has had great success in the treatment of cancer, the No. 1 cause of death in Hong Kong. We are excited to build on our initial work with Accuray to offer state-of-the-art advanced radiation treatments to patients. The Radixact and CyberKnife M6 Systems' unique modalities and precision will enable us to meet growing demand for high quality treatment and will play a key role in the armamentarium of state-of-the art technologies that form the backbone of the Hospital's arsenal against cancer," he added. For more information about the Accuray radiation therapy systems, visit www.accuray.com. For Important Safety Information please refer to http://www.accuray.com/safety-statement-radiation-treatment Accuray Incorporated (Nasdaq: ARAY) is a radiation oncology company that develops, manufactures and sells precise, innovative tumor treatment solutions that set the standard of care with the aim of helping patients live longer, better lives. The company's leading-edge technologies deliver the full range of radiation therapy and radiosurgery treatments. For more information, please visit www.accuray.com. Hong Kong Sanatorium & Hospital (HKSH) is one of the leading private hospitals in Hong Kong. It is owned by the Li Shu Fan Medical foundation (LSFMF). HKSH is committed to fulfilling LSFMF's vision of providing quality health care and advancing medical education and research, with an overriding concern for the public good. Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to clinical applications, clinical results, market acceptance of our new technologies, patient outcomes and Accuray's leadership position in radiation oncology innovation and technologies. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from expectations, including but not limited to the risks detailed from time to time under the heading "Risk Factors" in the company's report on Form 10-K, filed on August 24, 2016, the company's report on Form 10-Q, filed on November 1, 2016, and as updated periodically with the company's other filings with the SEC. Forward-looking statements speak only as of the date the statements are made and are based on information available to the company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.
Wang A.Y.-M.,University of Hong Kong |
Fang F.,Chinese University of Hong Kong |
Chan J.,Hong Kong Sanatorium Hospital |
Wen Y.-Y.,Chinese University of Hong Kong |
And 7 more authors.
Journal of the American Society of Nephrology | Year: 2014
Vitamin D seems to protect against cardiovascular disease, but the reported effects of vitaminDon patient outcomes in CKD are controversial. We conducted a prospective, double blind, randomized, placebocontrolled trial to determine whether oral activated vitamin D reduces left ventricular (LV)mass in patients with stages 3-5 CKD with LV hypertrophy. Subjects with echocardiographic criteria of LV hypertrophy were randomly assigned to receive either oral paricalcitol (1 μg) one time daily (n=30) ormatching placebo (n=30) for 52 weeks. The primary end point was change in LV mass index over 52 weeks, which was measured by cardiac magnetic resonance imaging. Secondary end points included changes in LV volume, echocardiographic measures of systolic and diastolic function, biochemical parameters of mineral bone disease, and measures of renal function. Change in LV mass index did not differ significantly between groups (median [interquartile range], 22.59 [26.13 to 0.32] g/m2 with paricalcitol versus 24.85 [29.89 to 1.10] g/m2 with placebo). Changes in LV volume, ejection fraction, tissue Doppler-derived measures of early diastolic and systolicmitral annular velocities, and ratio of earlymitral inflowvelocity to early diastolic mitral annular velocity did not differ between the groups. However, paricalcitol treatment significantly reduced intact parathyroid hormone (P,0.001) and alkaline phosphatase (P=0.001) levels as well as the number of cardiovascular-related hospitalizations compared with placebo. In conclusion, 52 weeks of treatment with oral paricalcitol (1 mg one time daily) significantly improved secondary hyperparathyroidism but did not alter measures of LV structure and function in patients with severe CKD. Copyright © 2014 by the American Society of Nephrology.
Wong A.T.C.,Hong Kong Sanatorium Hospital |
To R.M.Y.,Hong Kong Sanatorium Hospital |
Wong C.L.P.,Hong Kong Sanatorium Hospital |
Chan W.-K.,Hong Kong Sanatorium and Hospital |
Ma E.S.K.,Hong Kong Sanatorium Hospital
Diagnostic Molecular Pathology | Year: 2013
Activating mutations of the epidermal growth factor receptor (EGFR) gene in non-small cell lung cancer predict for a favorable clinical response to tyrosine kinase inhibitor therapy. Although Sanger sequencing is a conventional method to detect EGFR gene mutations, multiplex real-time allele-specific polymerase chain reaction (PCR) systems are increasingly used in the routine molecular diagnostic setting. We aim to evaluate 2 proprietary real-time PCR assays (cobas and therascreen) against Sanger sequencing in the detection of EGFR gene mutations. The overall concordance rate between cobas and therascreen assays with Sanger sequencing was 89% and 88%, respectively, and increased to 96% and 98%, respectively, if the mutations not covered were excluded. The cobas assay showed a superior coverage of exon 20 mutations, but L861Q was not targeted. The nature of specimen, DNA integrity, and tumor cell content are factors that affect the assay performance. DNA extracted from cell block and clot of pleural fluid gave rise to 1 invalid call and 1 false-negative result by the cobas assay and 1 missed T790M mutation and 1 false-negative result by the therascreen assay. Both assays are around 5 times more expensive compared with Sanger sequencing in terms of reagent cost. We conclude that both assays prove to be a rapid, simple, and validated method in detecting the most common and clinically significant EGFR gene mutations in non-small cell lung cancer. Although less convenient compared with real-time PCR assays, Sanger sequencing is cheaper in terms of reagent cost and allows the detection of rare or novel EGFR gene mutations. Copyright © 2013 by Lippincott Williams & Wilkins.
Chan H.H.L.,Hong Kong Sanatorium & Hospital |
Lo G.,Hong Kong Sanatorium & Hospital |
Cheung P.S.Y.,Hong Kong
Hong Kong Medical Journal | Year: 2016
Introduction: Screening mammogram can decrease the mortality of breast cancer. Studies show that women avoid mammogram because of fear of pain, diagnosis, and radiation. This study aimed to evaluate the effectiveness of a radiolucent pad (MammoPad; Hologic Inc, Bedford [MA], US) during screening mammogram to reduce pain in Chinese patients and the possibility of glandular dose reduction. Methods: This case series was conducted in a private hospital in Hong Kong. Between November 2011 and January 2012, a total of 100 Chinese patients were recruited to our study. Left mammogram was performed without MammoPad and served as a control. Right mammogram was performed with the radiolucent MammoPad. All patients were then requested to complete a simple questionnaire. The degree of pain and discomfort was rated on a 0-10 numeric analogue scale. Significant reduction in discomfort was defined as a decrease of 10% or more. Results: Of the 100 patients enrolled in this study, 66.3% of women reported at least a 10% reduction in the level of discomfort with the use of MammoPad. No statistical differences between age, breast size, and the level of discomfort were found. Conclusion: The use of MammoPad significantly reduced the level of discomfort experienced during mammography. Radiation dose was also reduced. © 2016, Hong Kong Academy of Medicine Press. All rights reserved.
Smith C.,Queensland Institute of Medical Research |
Tsang J.,University of Hong Kong |
Beagley L.,Queensland Institute of Medical Research |
Chua D.,Hong Kong Sanatorium Hospital |
And 8 more authors.
Cancer Research | Year: 2012
Nasopharyngeal carcinoma (NPC) is endemic in China and Southeast Asia where it is tightly associated with infections by Epstein-Barr virus (EBV). The role of tumor-associated viral antigens in NPC renders it an appealing candidate for cellular immunotherapy. In earlier preclinical studies, a novel adenoviral vector-based vaccine termed AdE1-LMPpoly has been generated that encodes EBV nuclear antigen-1 (EBNA1) fused to multiple CD8 + T-cell epitopes from the EBV latent membrane proteins, LMP1 and LMP2. Here, we report the findings of a formal clinical assessment of AdE1-LMPpoly as an immunotherapeutic tool for EBV-associated recurrent and metastatic NPC. From a total of 24 patients with NPC, EBV-specific T cells were successfully expanded from 16 patients with NPC (72.7%), whereas six patients with NPC (27.3%) showed minimal or no expansion of virus-specific T cells. Transient increase in the frequencies of LMP1&2- and EBNA1-specific T-cell responses was observed after adoptive transfer to be associated with grade I flu-like symptoms and malaise. The time to progression in these patients ranged from 38 to 420 days with a mean time to progression of 136 days. Compared with patients who did not receive T cells, the median overall survival increased from 220 to 523 days. Taken together, our findings show that adoptive immunotherapy with AdE1-LMPpoly vaccine is safe and well tolerated and may offer clinical benefit to patients with NPC. ©2012 AACR.
Peng P.W.H.,University of Toronto |
Li C.,Hong Kong Sanatorium Hospital |
Farcas E.,University of Toronto |
Haley A.,University of Toronto |
And 3 more authors.
British Journal of Anaesthesia | Year: 2010
Background. The objective of this study was to examine the effects of low-dose pregabalin on the analgesic efficacy, side-effects, and recovery profile in patients undergoing laparoscopic cholecystectomy. Methods. One hundred and sixty-two patients aged 18-65 yr, of ASA physical status I-III, undergoing elective outpatient laparoscopic cholecystectomy were recruited and randomized in this prospective, placebo-controlled, double-blind study to receive one of the following study medications orally: pregabalin 50 mg, pregabalin 75 mg, or placebo, 1 h before surgery and then every 12 h after operation for a total of three doses. Postoperative numeric pain scores, analgesic consumption, recovery score (QoR-40), and side-effects (opioid-related symptom distress scale) were assessed in the early postoperative period (every 15 min during the first hour, at 90, 120 min, 6, and 12 h) and at days 1, 2, and 7. Data were analysed using an intention-to-treat method. Results. Compared with the placebo group, the pain scores were lower in the pregabalin 75 mg group in the first 90 min after surgery (P<0.05). Pregabalin 50 mg resulted in pain reduction at 30 and 45 min (P<0.05) relative to placebo. The analgesic consumption, side-effects, and recovery scores were similar among the three groups. Conclusions. Perioperative administration of pregabalin 75 mg provided limited analgesic benefit in the postoperative period. An updated meta-analysis confirms this finding (see Supplementary material). © The Author . Published by Oxford University Press on behalf of the British Journal of Anaesthesia. All rights reserved.
Kwok O.H.,Hong Kong Sanatorium & Hospital
The Journal of invasive cardiology | Year: 2013
The development of modern coronary stent platforms has transformed the landscape of interventional cardiology. Contemporary coronary stents are much more deliverable than older-generation stents. However, longitudinal deformation has emerged as a "new" complication in modern coronary stent platforms. Although most reported cases of longitudinal stent deformation involve mechanical or technical mishaps, it appears that it is more frequently associated with a particular stent design: the "offset peak-to-peak" stent design. This review summarizes the latest data around stent performance. Within this context, two clinical cases where longitudinal deformation was observed in the absence of any mechanical mishaps are also presented. Collectively, this evidence suggests that stent design may be a major determinant of stent performance.
Chen S.,Hong Kong Sanatorium & Hospital
Clinical Nuclear Medicine | Year: 2016
ABSTRACT: A bedridden 90-year-old man with fever and elevated prostate-specific antigen (PSA) (49 ng/mL) was referred for differentiation between infection and tumor. F-FDG PET/CT was negative for infection, but Ga-PSMA PET/CT showed multiple lesions in prostate gland with infiltration to bladder wall and seminal vesicle, consistent with locally advanced prostate cancer. The lesion with the highest Ga-PSMA uptake was strongly avid for Ga-DOTATOC, suggesting neuroendocrine tumor differentiation. After hormonal therapy, PSA normalized, but chromogranin-A increased (from 251 to 398 ng/mL), inferring progression of neuroendocrine tumor differentiation. Advanced prostate cancer may require investigation for pathological neuroendocrine transformation, although PSA may suggest improvement. Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.
PubMed | Hong Kong Sanatorium & Hospital
Type: | Journal: Medical physics | Year: 2017
Tomotherapy delivers an intensity-modulated radiation therapy (IMRT) treatment by the synchronization of gantry rotation, multileaf collimator (MLC), and couch movement. This dynamic nature makes the quality assurance (QA) important and challenging. The purpose of this study is to develop some methodologies using an ArcCHECK for accurate QA measurements of the gantry angle and speed, MLC synchronization and leaf open time, couch translation per gantry rotation, couch speed and uniformity, and constancy of longitudinal beam profile for a Tomotherapy unit.Four test plans recommended by AAPM Task Group 148 (TG148) and the manufacturer were chosen for this study. Helical and static star shot tests are used for checking the leaves opened at the expected gantry angles. Another helical test is to verify the couch traveled the expected distance per gantry rotation. The final test is for checking the couch speed constancy with a static gantry. ArcCHECK can record the detector signal every 50 ms as a movie file, and has a virtual inclinometer for gantry angle measurement. These features made the measurement of gantry angle and speed, MLC synchronization and leaf open time, and longitudinal beam profile possible. A shaping parameter was defined for facilitating the location of the beam center during the plan delivery, which was thereafter used to calculate the couch translation per gantry rotation and couch speed. The full width at half maximum (FWHM) was calculated for each measured longitudinal beam profile and then used to evaluate the couch speed uniformity. Furthermore, a mean longitudinal profile was obtained for constancy check of field width. The machine trajectory log data were also collected for comparison. Inhouse programs were developed in MATLAB to process both the ArcCHECK and machine log data.The deviation of our measurement results from the log data for gantry angle was calculated to be less than 0.4. The percentage differences between measured and planned leaf open time were found to be within 0.5% in all the tests. Our results showed mean values of MLC synchronization of 0.982, 0.983, and 0.995 at static gantry angle 0, 45, and 135, respectively. The mean value of measured couch translation and couch speed by ArcCHECK had less than 0.1% deviation from the planned values. The variation in the value of FWHM suggested the couch speed uniformity was better than 1%. The mean of measured longitudinal profiles was suitable for constancy check of field width.Precise and efficient methods for measuring the gantry angle and speed, leaf open time, couch translation per gantry rotation, couch speed and uniformity, and constancy of longitudinal beam profile of Tomotherapy using ArcCHECK have been developed and proven to be accurate compared with machine log data. Estimation of the Tomotherapy binary MLC leaf open time is proven to be precise enough to verify the leaf open time as small as 277.8 ms. Our method also makes the observation and quantification of the synchronization of leaves possible.